How do I set a price alert for GOSS?

To set a GOSS price alert on Stock Alarm Pro, navigate to the GOSS quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for GOSS?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for GOSS. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for GOSS?

Stock Alarm Pro supports over 125 trigger types for GOSS: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about GOSS price changes?

GOSS alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for GOSS alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for GOSS and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Gossamer Bio, Inc.(GOSS)

$11.85—

WatchlistAsk AI Chart

Gossamer Bio, Inc.(GOSS)

NASDAQAbout this data

$11.85—

WatchlistAsk AI Chart Studio

GOSS(GOSS)

GOSS

10/1/26

Gossamer Bio (GOSS)

Thursday

6:31 AM

ThesisGossamer Bio: the risks are mounting — Binary clinical trial risk - Phase 3 seralutinib failure would eliminate primary value driver and likely trigger…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$48M	$36M	$17M
Rev. Growth	-57.7%	-26.0%	-53.3%
EPS	$-59.64	$-15.62	$-10.52
EPS Growth	-198%	+73.8%	+32.6%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $36M — -26.0% growth in a single year.

What Could Go Wrong

01Binary clinical trial risk - Phase 3 seralutinib failure would eliminate primary value driver and likely trigger significant equity decline (70-90% downside typical for failed lead assets). PAH is competitive market with established therapies.
02Capital markets dependency - company requires additional financing before potential commercialization in 2027-2028. Biotech financing windows can close rapidly during market stress, forcing dilutive raises or program cuts.
03Regulatory approval uncertainty - FDA standards for PAH therapies require demonstrable improvement in hemodynamic parameters and functional capacity. Advisory committee rejections or clinical holds can extend timelines 12-24+ months.
04Merck's sotatercept (approved March 2024 for PAH) has established first-mover advantage in novel mechanism category, potentially limiting seralutinib's market opportunity and pricing power
05United Therapeutics dominates PAH market with multiple approved products (Tyvaso, Remodulin, Orenitram) and deep KOL relationships, creating high barriers for new entrants to gain formulary access and physician adoption
06Acceleron/Merck, Janssen, and other large pharma have well-funded PAH programs that could produce superior efficacy data or reach market faster
07Negative equity position (ROE of 593.8% with negative book value) indicates accumulated deficits exceed assets, typical for pre-revenue biotechs but signals extended cash burn history
08Estimated 12-18 month cash runway based on current burn rate requires near-term financing, likely in 2026-2027, creating dilution risk and dependence on favorable market conditions

FY2025 Snapshot

Revenue: $48M
Rev. Growth: -57.7%
Gross Margin: 97.9%
Op. Margin: -337%
Net Margin: -351%
Net Income: $-170M
NI Growth: -201%
EPS: $-59.64
1Y Return: -94.7%

GOSS Chart

My Notes

growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts.
Rising interest rates negatively impact Gossamer through two primary channels: (1) Valuation compression - clinical-stage biotechs are…
Watch on earnings: Seralutinib Phase 3 trial enrollment completion and data readout timing (expected 2026-2027 based on typical trial durations), Quarterly cash burn rate and ending cash balance to assess runway and financing urgency, NASDAQ Biotechnology Index (NBI) performance as proxy for biotech financing environment and sector sentiment.

One Sentence Summary:

The bear case: binary clinical trial risk - phase 3 seralutinib failure would eliminate primary value driver and likely trigger significant equity decline (70-90%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

—

What Could Go Wrong

01Binary clinical trial risk - Phase 3 seralutinib failure would eliminate primary value driver and likely trigger significant equity decline (70-90% downside typical for failed lead assets). PAH is competitive market with established therapies.

02Capital markets dependency - company requires additional financing before potential commercialization in 2027-2028. Biotech financing windows can close rapidly during market stress, forcing dilutive raises or program cuts.

03Regulatory approval uncertainty - FDA standards for PAH therapies require demonstrable improvement in hemodynamic parameters and functional capacity. Advisory committee rejections or clinical holds can extend timelines 12-24+ months.

04Merck's sotatercept (approved March 2024 for PAH) has established first-mover advantage in novel mechanism category, potentially limiting seralutinib's market opportunity and pricing power

05United Therapeutics dominates PAH market with multiple approved products (Tyvaso, Remodulin, Orenitram) and deep KOL relationships, creating high barriers for new entrants to gain formulary access and physician adoption

06Acceleron/Merck, Janssen, and other large pharma have well-funded PAH programs that could produce superior efficacy data or reach market faster

07Negative equity position (ROE of 593.8% with negative book value) indicates accumulated deficits exceed assets, typical for pre-revenue biotechs but signals extended cash burn history

08Estimated 12-18 month cash runway based on current burn rate requires near-term financing, likely in 2026-2027, creating dilution risk and dependence on favorable market conditions

My Notes

growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts.

Rising interest rates negatively impact Gossamer through two primary channels: (1) Valuation compression - clinical-stage biotechs are…

Watch on earnings: Seralutinib Phase 3 trial enrollment completion and data readout timing (expected 2026-2027 based on typical trial durations), Quarterly cash burn rate and ending cash balance to assess runway and financing urgency, NASDAQ Biotechnology Index (NBI) performance as proxy for biotech financing environment and sector sentiment.